Browse the evidence

GLP-1 receptor agonists reduce systolic blood pressure by 1.7 to 10.6 mmHg compared to placebo, contributing to stroke risk reduction.

GLP-1 drugs can help lower blood pressure, which is a key factor in preventing stroke. This effect is seen across different drugs in this class, with some showing reductions of up to 10 mmHg.

GLP-1 receptor agonists reduce the risk of atrial fibrillation by approximately 42% compared to placebo, which is a significant risk factor for stroke.

Taking GLP-1 drugs may also lower your risk of developing atrial fibrillation, a heart rhythm problem that increases stroke risk. This is another way these drugs protect your brain and heart.

Genetically proxied GLP-1R-based multi-target agonists (GIPR/GLP-1R, GCGR/GLP-1R, and GCGR/GIPR/GLP-1R) causally reduce the risk of Metabolic dysfunction-associated steatotic liver disease (MASLD) and its complications, including liver cancer and cardiovascular disease, partly independent of weight loss.

Genetic evidence strongly supports that GLP-1-based therapies (like semaglutide or tirzepatide) reduce the risk of fatty liver disease and its complications (liver cancer, heart disease). This benefit appears to come from improving metabolic health (insulin sensitivity, lipids) directly, not just from losing weight. If you have MASLD, these medications are a promising therapeutic option to discuss with your doctor, regardless of your current weight loss progress.

Discontinuation of semaglutide leads to significant weight regain ('semaglutide rebound'), with studies showing approximately two-thirds of lost weight is regained within one year.

If you stop taking semaglutide, expect to regain about two-thirds of the weight you lost within a year. This 'rebound' effect is common. Plan for sustainable lifestyle changes or discuss long-term management strategies with your doctor before stopping.

GLP-1 receptor agonists (semaglutide, tirzepatide) and dual agonists produce significant weight loss (15-22.5%) but are associated with lean muscle mass loss and require long-term adherence.

GLP-1 drugs like semaglutide and tirzepatide are highly effective for weight loss (15-22%), but you must take them long-term to maintain results. They can cause muscle loss, so combine them with resistance training and high protein intake. Be aware of GI side effects and contraindications like thyroid cancer history.

Performing bariatric surgery (Roux-en-Y or sleeve gastrectomy) prior to abdominoplasty significantly reduces postoperative complications and improves long-term stability compared to abdominoplasty alone in patients with metabolic syndrome.

If you have significant excess abdominal skin and metabolic issues (high blood pressure, diabetes, or high cholesterol), do not rush into skin removal surgery. You must first lose weight through diet, medication (like GLP-1s), or bariatric surgery until your weight and metabolic markers are stable for at least 6-12 months. This sequence drastically lowers your risk of infection, blood clots, and poor scarring, and ensures the skin removal looks good long-term.

Initiation of GLP-1 receptor agonists in adults with obesity or type 2 diabetes is associated with a substantially reduced risk of all-cause mortality, with the survival benefit being more pronounced in patients under 65 years of age and those with cardiometabolic comorbidities.

If you have obesity or type 2 diabetes, starting a GLP-1 RA (like semaglutide or liraglutide) is strongly associated with living longer, especially if you are under 65 or have other heart/kidney risks. While there is a small, early risk of pancreatitis, the survival benefit is substantial. Discuss this risk-benefit profile with your doctor, particularly if you have a history of pancreatic issues.

GLP-1 and GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) cause a significant reduction in skeletal muscle mass (30-40% of total weight loss), posing a risk for sarcopenia, particularly in elderly patients and those with type 2 diabetes.

If you are taking semaglutide or tirzepatide, expect to lose some muscle along with fat. To protect your strength, you must eat more protein (at least 1.2g/kg/day) and perform resistance training 2-3 times per week. This is especially critical if you are older or already have low muscle mass.

GLP-1 receptor agonists lower blood pressure through central sympathetic inhibition, natriuresis, and improved endothelial function, with effects largely independent of weight loss.

GLP-1 drugs (like Ozempic or Wegovy) lower blood pressure through multiple pathways: they calm the nervous system's stress response, help kidneys excrete salt, and improve blood vessel health. This happens even before significant weight loss occurs.

MC4R agonists significantly reduce triglyceride and LDL-C levels, and lower systolic blood pressure, but have no significant effect on fasting blood sugar, HbA1c, or diastolic blood pressure.

MC4R agonists not only help you lose weight but also significantly improve your lipid profile by lowering triglycerides and LDL cholesterol, and they can lower systolic blood pressure. However, they do not appear to have a significant effect on fasting blood sugar, HbA1c, or diastolic blood pressure. These metabolic benefits make them a valuable treatment for reducing overall cardiovascular risk in patients with obesity.

Orforglipron 36 mg is the optimal dose for improving lipid profiles (triglycerides, total cholesterol) and blood pressure while maintaining better tolerability than 45 mg.

If your main goal is improving cholesterol and blood pressure rather than maximum weight loss, the 36 mg dose of orforglipron offers a good balance of efficacy and tolerability.

GLP-1 receptor agonists are associated with an increased risk of gallbladder and biliary tract diseases, particularly in obese individuals undergoing rapid weight loss, though the risk for pancreatitis is not consistently supported by recent large-scale data.

Be aware that GLP-1 medications slightly increase the risk of gallbladder issues, especially if you lose weight quickly. However, recent data suggests the risk of pancreatitis is not significantly higher than with other treatments. Discuss your personal risk factors with your doctor, who may recommend monitoring.

Early rapid weight loss (≥15% by Week 24) with incretin-based obesity medications (tirzepatide or semaglutide) predicts greater overall efficacy (higher probability of achieving ≥25-30% total weight loss) without negatively impacting study completion rates, despite a numerically higher incidence of gastrointestinal and hepatobiliary adverse events.

If you are starting tirzepatide or semaglutide, losing weight quickly in the first few months is a good sign that you will likely achieve your long-term weight loss goals. While you may experience more stomach issues early on, this does not mean you will quit treatment. Monitor your health, manage side effects as needed, and trust that early rapid response is a positive predictor of success.

Flexible, gradual titration of GLP-1 receptor agonists significantly reduces nausea and vomiting rates and discontinuation compared to standard rapid titration without compromising weight loss efficacy.

When starting a GLP-1 medication like semaglutide, do not rush to the highest dose. Start at the lowest possible dose and increase it slowly. If you feel mild nausea, pause the dose increase until it passes. If you vomit or feel significantly unwell, go back to the last dose that felt okay. This 'start low and go slow' approach prevents side effects and keeps you on the medication long enough to lose weight, which is the actual goal. You do not need to reach the maximum dose to get benefits; your body's tolerance is your guide.

Tirzepatide demonstrates superior weight reduction compared to Semaglutide 2.4 mg and significant MASH resolution in patients with histologically-proven MASH.

Tirzepatide is a once-weekly injection for diabetes and obesity that also shows strong promise for treating MASH. It reduces liver fat and inflammation significantly, with higher doses showing better results. It also leads to greater weight loss than Semaglutide in head-to-head comparisons.

Semaglutide improves cardiovascular risk factors, including blood pressure and heart failure symptoms, in patients with obesity.

Semaglutide may help lower blood pressure and improve heart function in obese patients with heart failure, in addition to aiding weight loss.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) induce weight loss by delaying gastric emptying and increasing satiety, but long-term cost-effectiveness modeling is hindered by uncertainty regarding sustained BMI trajectories and weight regain upon cessation.

GLP-1 medications like semaglutide and tirzepatide work by slowing digestion and reducing hunger, leading to significant weight loss. However, these drugs are not a one-time cure. Stopping treatment typically leads to weight regain, suggesting that obesity management with these agents is likely a long-term commitment. Cost-effectiveness models struggle to predict long-term outcomes because clinical trials are short, making it difficult to know if the weight loss will be sustained indefinitely.

Ultra-processed food (UPF) consumption drives overconsumption and weight gain independently of macronutrient composition, energy density, or fiber content, primarily by hijacking brain reward systems and creating neurological addiction.

Stop blaming yourself for lack of willpower. Your brain's reward system is likely hijacked by ultra-processed foods, making it biologically difficult to stop eating. Focus on eliminating UPFs entirely (abstinence) rather than trying to moderate them, as this addresses the root neurological cause of overconsumption.

Phentermine-topiramate produces greater weight loss than GLP-1 receptor agonists, but GLP-1 agonists carry a higher risk of adverse events.

If you are looking for the maximum possible weight loss number, phentermine-topiramate may outperform GLP-1 drugs like semaglutide. However, this comes with a higher risk of side effects. GLP-1s offer a better safety profile regarding adverse events and provide proven cardiovascular protection, making them a preferred choice for patients with heart disease risks despite slightly lower weight loss efficacy.

SGLT2 inhibitors and GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) provide clinical benefits in obesity-related HFpEF, including symptom improvement and potential reverse cardiac remodeling, independent of or in addition to weight loss.

If you have obesity and heart failure with preserved ejection fraction, ask your doctor about SGLT2 inhibitors (like dapagliflozin) or GLP-1 agonists (like semaglutide). These drugs not only help with weight but also directly protect the heart by reducing inflammation and stiffness, improving symptoms and outcomes.

Discontinuation of obesity management medications (OMMs) such as tirzepatide or semaglutide leads to substantial weight regain and partial reversal of cardiometabolic improvements, indicating that sustained treatment is required to maintain health benefits.

If you stop taking your obesity medication (like tirzepatide or semaglutide), you will likely regain most of the weight you lost, even if you keep your diet and exercise habits. To keep the health benefits, you generally need to stay on the medication long-term.

Incretin-based therapies (GLP-1 and GIP/GLP-1 RAs) produce clinically significant weight loss and improve weight-related comorbidities, but their implementation is hindered by high costs, insurance coverage barriers, supply shortages, and gastrointestinal adverse events.

Incretin-based therapies like semaglutide and tirzepatide are highly effective for weight loss and improving health conditions like diabetes and heart disease. However, access is difficult due to high costs, insurance restrictions, and supply shortages. Side effects like nausea are common but often improve over time. Patients should work with pharmacists to navigate coverage and manage side effects through careful dosing.

SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) significantly reduce cardiovascular mortality and heart failure hospitalization in type 2 diabetes patients, while also reducing liver fat content and improving liver enzymes in those with MASLD.

If you have Type 2 Diabetes and fatty liver disease, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs are proven to significantly lower your risk of heart failure and death, and they also help reduce fat in your liver. They are a key part of modern care for this condition.

GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) reduce major adverse cardiovascular events (MACE) and promote histological resolution of MASH in patients with T2D and MASLD.

If you have Type 2 Diabetes and fatty liver disease, ask your doctor about GLP-1 receptor agonists (like semaglutide or liraglutide). These drugs are proven to significantly lower your risk of heart attacks and strokes, and they can even reverse liver inflammation (MASH) in some patients. They are a key part of modern care for this condition.